National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Adult Hodgkin Lymphoma Treatment (PDQ®)
Patient Version   Health Professional Version   En español   Last Modified: 03/10/2009



Purpose of This PDQ Summary






General Information About Adult Hodgkin Lymphoma






Cellular Classification of Adult Hodgkin Lymphoma






Stage Information for Adult Hodgkin Lymphoma






Treatment Option Overview






Early Favorable Hodgkin Lymphoma






Early Unfavorable Hodgkin Lymphoma






Advanced Favorable Hodgkin Lymphoma






Advanced Unfavorable Hodgkin Lymphoma






Recurrent Adult Hodgkin Lymphoma






Hodgkin Lymphoma During Pregnancy






Get More Information From NCI






Changes to This Summary (03/10/2009)






More Information



Page Options
Print This Page
Print Entire Document
View Entire Document
E-Mail This Document
Quick Links
Director's Corner

Dictionary of Cancer Terms

NCI Drug Dictionary

Funding Opportunities

NCI Publications

Advisory Boards and Groups

Science Serving People

Español
Quit Smoking Today
NCI Highlights
The Nation's Investment in Cancer Research FY 2010

Report to Nation Finds Declines in Cancer Incidence, Death Rates

High Dose Chemotherapy Prolongs Survival for Leukemia

Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E
General Information About Adult Hodgkin Lymphoma

Related Summaries
Statistics



Related Summaries

Other PDQ summaries containing information related to Hodgkin lymphoma include:

Statistics

Note: Estimated new cases and deaths from Hodgkin lymphoma in the United States in 2008:[1]

  • New cases: 8,220.
  • Deaths: 1,350.

More than 75% of all newly diagnosed patients with adult Hodgkin lymphoma (HL) can be cured with combination chemotherapy and/or radiation therapy.[2] National mortality has fallen more rapidly for adult HL than for any other malignancy over the last 5 decades.[2]

Prognosis for a given patient depends on several factors. The most important factors are the presence or absence of systemic symptoms, the stage of disease, presence of large masses, and the quality and suitability of the treatment administered. Other important factors are age (therapy for very young children requires special attention), sex, erythrocyte sedimentation rate, extent of abdominal involvement, hematocrit, and absolute number of nodal sites of involvement.[3,4]

HL is the main cause of death over the first 15 years after treatment. By 15 to 20 years after therapy, the cumulative mortality from a second malignancy will exceed the cumulative mortality from HL.[5-7]

References

  1. American Cancer Society.: Cancer Facts and Figures 2008. Atlanta, Ga: American Cancer Society, 2008. Also available online. Last accessed October 1, 2008. 

  2. Brenner H, Gondos A, Pulte D: Ongoing improvement in long-term survival of patients with Hodgkin disease at all ages and recent catch-up of older patients. Blood 111 (6): 2977-83, 2008.  [PUBMED Abstract]

  3. American Cancer Society.: Cancer Facts and Figures 2007. Atlanta, Ga: American Cancer Society, 2007. Also available online. Last accessed February 17, 2009. 

  4. Cosset JM, Henry-Amar M, Meerwaldt JH, et al.: The EORTC trials for limited stage Hodgkin's disease. The EORTC Lymphoma Cooperative Group. Eur J Cancer 28A (11): 1847-50, 1992.  [PUBMED Abstract]

  5. Mauch PM, Kalish LA, Marcus KC, et al.: Long-Term Survival in Hodgkin's Disease Cancer J Sci Am 1 (1): 33-42, 1995.  [PUBMED Abstract]

  6. Aisenberg AC: Problems in Hodgkin's disease management. Blood 93 (3): 761-79, 1999.  [PUBMED Abstract]

  7. Aleman BM, van den Belt-Dusebout AW, Klokman WJ, et al.: Long-term cause-specific mortality of patients treated for Hodgkin's disease. J Clin Oncol 21 (18): 3431-9, 2003.  [PUBMED Abstract]

Back to Top

< Previous Section  |  Next Section >


A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov